

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	Satishchandran, C. et al.	Examiner:	CHONG, Kimberly
Serial No.:	10/009,134	Group Art Unit:	1635
Filed:	October 20, 2002		
Entitled:	Methods and Compositions for Inhibiting the Function of Polynucleotide Sequences	Conf. No.:	5538

Mail Stop AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUBSTANCE OF EXAMINER INTERVIEW

Dear Sir:

In response to the Interview Summary mailed September 27, 2010 in the above-noted Patent Application, and in accord with 37 C.F.R. 1.133(b), Applicants now provide the following statement of the substance of the in-person interview conducted September 22, 2010.

Applicant's representatives met with Examiner Chong to discuss the obviousness rejections of record, particularly with regard to the reliance on antisense- and ribozyme-related art to support the rejections.

Examiner Chong clarified her position regarding the conclusion of obviousness as being based on knowledge in the art that multiple genes or multiple regions of the same gene could be targeted using vectors expressing two ribozymes or antisense molecules. The Examiner submitted that it would have been obvious to make a multitarget dsRNA vector given dsRNA has been shown to be efficacious at gene silencing and that vectors expressing a single dsRNA have been delivered to cells.

Examiner Chong agreed to consider evidence provided in a declaration explaining why one of skill in the art would not have expected a multitarget dsRNA to work in view of what was known in the art at the time.

Applicant notes that in the Interview Summary mailed September 27, 2010, the Examiner states the following:

"The Examiner suggested the Applicant provide evidence that there was no reasonable expectation of success at making a multitarget dsRNA and delivering to cells such that when each dsRNA is cleaved out of the vector, each of the dsRNA would not be expected to work effectively."

Solely in the interest of having an accurate record, Applicants wish to point out that in the current claims, the dsRNAs are not "cleaved out of a vector," but rather can be prepared from a transcript or transcripts.

This summary is filed within one month or thirty days from the mailing of the Interview Summary (October 27, 2010). This statement is timely filed.

The Commissioner is hereby authorized to charge any additional fees associated with this communication to Deposit Account No. 50-0850.

Respectfully submitted:

Date: October 27, 2010

/Mark J. FitzGerald/

Mark J. FitzGerald
Reg. No. 45,928
Attorney for Applicants
NIXON PEABODY LLP
100 Summer Street
Boston, MA 02110-2131
(617) 345-1058